2. Academic Validation
  3. Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin

Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin

  • J Antibiot (Tokyo). 2023 Oct 23. doi: 10.1038/s41429-023-00663-6.
Thomas Nittoli 1,  Anna Brotcke Zumsteg 2,  Abira Bandyopadhyay 2,  Stephanie Federici 2,  Alida Coppi 2,  Susan Jorgenson 2,  Seung-Yong Choi 3,  Mrinmoy Saha 3,  Benjamin Wertz 3,  Priyanka Trivedi 2,  Chandrashekhar Korgaonkar 2,  Harvey Chin 2,  Onson Luong 2,  Christos Kyratsous 2,  William Olson 2
Affiliations

Affiliations

  • 1 Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. [email protected].
  • 2 Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.
  • 3 Abzena, 360 George Patterson Blvd, Bristol, PA, 19007, USA.
PMID: 37872357 DOI: 10.1038/s41429-023-00663-6
Abstract

For a number of years, antimicrobial resistance (AMR) has been a critical issue for humanity. Drug discovery efforts have been very limited and the spread of Bacterial pathogens has over-run our traditional arsenal of Antibiotics. Bacteria can involve to evade compounds that can halt their rapid growth. The authors have discovered a potent macrocycle derivative that when dosed concomitantly with the standard of care (SOC) Antibiotic vancomycin, can clear methicillin resistant Staphylococcus aureus (MRSA) infections. In addition, we have probed the lead compounds in Salmonella typhimurium Bacterial strains. In vitro, in vivo, and ADME data have been included to stress the virtues of this new Antibiotic.

Figures
Products